Evidence map›Paper›PMID 37496307›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2023

Sex and APOE ε4 carrier effects on atrophy, amyloid PET, and tau PET burden in early-onset Alzheimer's disease.

Sára Nemes, Paige E Logan, Mohit K Manchella, Nidhi S Mundada, Renaud La Joie, Angelina J Polsinelli, Dustin B Hammers, Robert A Koeppe, Tatiana M Foroud, Kelly N Nudelman and 40 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Distinct Tau PET Dynamics in Early vs. Late Age-of-Onset Alzheimer's disease.medRxiv : the preprint server for health sciences · 2026
    Article
  9. Alzheimer's disease polygenic risk in early- and late-onset Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Sex andInternational journal of molecular sciences · 2025
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Integrating plasma p-tau217 and digital cognitive assessments for early detection in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

50 authors at 20 institutions in 1 country.

Sára NemesDepartment of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.ORCID 0000-0003-1483-3719
Paige E LoganDepartment of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.ORCID 0000-0002-2058-2082
Mohit K ManchellaDepartment of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Nidhi S MundadaDepartment of Neurology, University of California, San Francisco, California, USA.
Renaud La JoieDepartment of Neurology, University of California, San Francisco, California, USA.
Angelina J PolsinelliDepartment of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Dustin B HammersDepartment of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Robert A KoeppeDepartment of Radiology, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Tatiana M ForoudDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Kelly N NudelmanDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Ani EloyanDepartment of Biostatistics, Center for Statistical Sciences, Brown University, Providence, Rhode Island, USA.
Leonardo IaccarinoDepartment of Neurology, University of California, San Francisco, California, USA.
Valérie Dorsant-ArdónDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Alexander TauroneDepartment of Biostatistics, Center for Statistical Sciences, Brown University, Providence, Rhode Island, USA.
Maryanne ThangarajahDepartment of Biostatistics, Center for Statistical Sciences, Brown University, Providence, Rhode Island, USA.
Jeffery L DageDepartment of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Paul AisenAlzheimer's Therapeutic Research Institute, University of Southern California, San Diego, California, USA.
Lea T GrinbergDepartment of Neurology, University of California, San Francisco, California, USA.
Clifford R JackDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Joel KramerDepartment of Neurology, University of California, San Francisco, California, USA.
Walter A KukullDepartment of Epidemiology, University of Washington, Seattle, Washington, USA.
Melissa E MurrayDepartment of Neurology, Mayo Clinic, Jacksonville, Florida, USA.
Malia RumbaughDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
David N Soleimani-MeigooniDepartment of Neurology, University of California, San Francisco, California, USA.
Arthur TogaLaboratory of Neuro Imaging, USC Stevens Neuroimaging and Informatics Institute, Keck School of Medicine of USC, Los Angeles, California, USA.
Alexandra TouroutoglouDepartment of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Prashanthi VemuriDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Alireza AtriBanner Sun Health Research Institute, Sun City, Arizona, USA.
Gregory S DayDepartment of Neurology, Mayo Clinic, Jacksonville, Florida, USA.
Ranjan DuaraDepartment of Neurology, Center for Mind/Brain Medicine, Brigham & Women's Hospital & Harvard Medical School, Boston, Massachusetts, USA.
Neill R Graff-RadfordDepartment of Neurology, Mayo Clinic, Jacksonville, Florida, USA.
Lawrence S HonigTaub Institute and Department of Neurology, Columbia University Irving Medical Center, New York, New York, USA.
David T JonesDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Joseph MasdeuNantz National Alzheimer Center, Houston Methodist and Weill Cornell Medicine, Houston, Texas, USA.
Mario F MendezDepartment of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Erik MusiekDepartment of Neurology, Washington University in St. Louis, St. Louis, Missouri, USA.
Chiadi U OnyikeDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Meghan RiddleDepartment of Neurology, Alpert Medical School, Brown University, Providence, Rhode Island, USA.
Emily RogalskiDepartment of Psychiatry and Behavioral Sciences, Mesulam Center for Cognitive Neurology and Alzheimer's Disease, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Stephen SallowayDepartment of Neurology, Alpert Medical School, Brown University, Providence, Rhode Island, USA.
Sharon J ShaDepartment of Neurology and Neurological Sciences, Stanford University, Palo Alto, California, USA.
Raymond S TurnerDepartment of Neurology, Georgetown Universit, Washington, District of Columbia, USA.
Thomas S WingoDepartment of Neurology and Human Genetics, Emory University School of Medicine, Atlanta, Georgia, USA.
Kyle B WomackDepartment of Neurology, Washington University in St. Louis, St. Louis, Missouri, USA.
David A WolkDepartment of Human Genetics, Emory University School of Medicine, Atlanta, Georgia, USA.
Gil D RabinoviciDepartment of Neurology, University of California, San Francisco, California, USA.
Maria C CarrilloMedical & Scientific Relations Division, Alzheimer's Association, Chicago, Illinois, USA.
Bradford C DickersonDepartment of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Liana G ApostolovaDepartment of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
LEADS Consortium
Indiana University School of MedicineUniversity of California, San Francisco · USBrown University · USJacksonville College · USMayo Clinic · USEmory University · USHarvard University · USWashington University in St. Louis · USAlzheimer's Association · USBanner Sun Health Research Institute · USBrigham and Women's Hospital · USColumbia University Irving Medical Center · USGeorgetown University · USHouston Methodist · USJohns Hopkins University · USNorthwestern University · USStanford University · USUniversity of California, Los Angeles · USUniversity of Michigan · USUniversity of Southern California · US

Funding

National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD)U24AG021886 · NIA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI TATIANA M. FOROUD · 2002 to 2026
$119.8M
Early Onset AD Consortium - the LEAD Study (LEADS)U01AG057195 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI APOSTOLOVA, LIANA G, CARRILLO, MARIA C · 2018 to 2023
$70.3M
National Alzheimer's Coordinating CenterU24AG072122 · NIA · UNIVERSITY OF WASHINGTON · PI STEPHENS, KARI A · 2021 to 2025
$45.8M
Research Education ComponentP30AG010133 · NIA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI GHETTI, BERNARDINO FRANCESCO · 1991 to 2020
$37.3M
Research Education ComponentP30AG062422 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Gil Dan Rabinovici · 2019 to 2026
$36.9M
Research Education ComponentP30AG062421 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI STEVEN E ARNOLD · 2019 to 2026
$36.5M
Research Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI NILUFER ERTEKIN-TANER · 2019 to 2026
$33.5M
Research Education CoreP30AG066462 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Miguel Arce · 2020 to 2026
$30.1M
Research Education ComponentP30AG066507 · NIA · JOHNS HOPKINS UNIVERSITY · PI MARILYN S. ALBERT · 2020 to 2026
$29.3M
The Goizueta Alzheimer's Disease Research CenterP30AG066511 · NIA · EMORY UNIVERSITY · PI Amy D Rodriguez · 2020 to 2026
$29.0M
Stanford Alzheimer's Disease Research CenterAdmin Supp: Developing iPSC models for AD and PDP30AG066515 · NIA · STANFORD UNIVERSITY · PI ELIZABETH MORMINO · 2020 to 2026
$29.0M
Research Education ComponentP30AG066444 · NIA · WASHINGTON UNIVERSITY · PI DAVID M. HOLTZMAN · 2020 to 2026
$28.7M
NIA NIH HHS P30 AG010133NIA NIH HHS P30 AG062421NIA NIH HHS P30 AG062422NIA NIH HHS P30 AG062677NIA NIH HHS P30 AG066444NIA NIH HHS P30 AG066462NIA NIH HHS P30 AG066506NIA NIH HHS P30 AG066507NIA NIH HHS P30 AG066511NIA NIH HHS P30 AG066515NIA NIH HHS P30 AG066530NIA NIH HHS P30 AG072976NIA NIH HHS P30 AG072977NIA NIH HHS P30 AG072979NIA NIH HHS P30 AG072980NIA NIH HHS R01 AG057739NIA NIH HHS R37 AG057739NIA NIH HHS R56 AG057195NIA NIH HHS U01 AG057195NIA NIH HHS U24 AG021886NIA NIH HHS U24 AG072122NIDCD NIH HHS K23 DC016912
6 · The paper itself

Abstract

introductionWe used sex and apolipoprotein E ε4 (APOE ε4) carrier status as predictors of pathologic burden in early-onset Alzheimer's disease (EOAD).

methodsWe included baseline data from 77 cognitively normal (CN), 230 EOAD, and 70 EO non-Alzheimer's disease (EOnonAD) participants from the Longitudinal Early-Onset Alzheimer's Disease Study (LEADS). We stratified each diagnostic group by males and females, then further subdivided each sex by APOE ε4 carrier status and compared imaging biomarkers in each stratification. Voxel-wise multiple linear regressions yielded statistical brain maps of gray matter density, amyloid, and tau PET burden.

resultsEOAD females had greater amyloid and tau PET burdens than males. EOAD female APOE ε4 non-carriers had greater amyloid PET burdens and greater gray matter atrophy than female ε4 carriers. EOnonAD female ε4 non-carriers also had greater gray matter atrophy than female ε4 carriers. DISCUSSION: The effects of sex and APOE ε4 must be considered when studying these populations. HIGHLIGHTS: Novel analysis examining the effects of biological sex and apolipoprotein E ε4 (APOE ε4) carrier status on neuroimaging biomarkers among early-onset Alzheimer's disease (EOAD), early-onset non-AD (EOnonAD), and cognitively normal (CN) participants. Female sex is associated with greater pathology burden in the EOAD cohort compared to male sex. The effect of APOE ε4 carrier status on pathology burden was the most impactful in females across all cohorts.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAmyloidogenic ProteinsApolipoprotein E4AtrophyBiomarkersFemaleHumansMaleNeuroimagingAmyloid beta-PeptidesAmyloidogenic ProteinsApolipoprotein E4Biomarkersamyloid PETAPOE ε4early-onset Alzheimer's diseaseearly-onset non-Alzheimer's diseasegeneticsimaging biomarkersMRIneuroimagingsex differencestau PET

Identifiers

PMID37496307
PMCPMC10811272
OpenAlexW4385294686

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.